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Abstract
Background: Despite a relatively young average age and no routine screening, prostate cancer is one of the most
common cancers in men who worked at the World Trade Center (WTC) following the 9/11/2001 disaster. This study
evaluated whether re-experiencing stressful memories of a traumatic event was associated with prostate cancer
incidence.
Methods: Participants were males from one clinical center that monitors the health of first-responders (N = 6857).
Monitoring began in July 2002 and occurs annually but does not include prostate cancer screening. Severity of
physical exposures and of re-experiencing memories and stress responses were measured at study enrollment
using standardized and validated methods in all participants. The outcome was incidence of diagnosed prostate
cancer after enrollment (n = 68). Bivariate analyses provided age-adjusted incidence rates (aIR). Cox proportional
hazards modeling was used to calculate incidence; hazards ratios (HR) were reported.
Results: The mean age of responders on 9/11/2001 was 37.9 years. Prostate cancer incidence was lowest in
responders with no re-experiencing stress (aIR = 250.83/100,000 person-years, [233.41–268.25]) and highest in
responders with severe re-experiencing stress (aIR = 818.49/100,000 person-years, [801.07–835.91]). Cox proportional
hazards regression revealed that re-experiencing the stressful events of 9/11/2001 was associated with increased
prostate cancer incidence (HR = 1.96 [1.26–3.05], P = 0.003), even upon adjusting for confounders.
Conclusions: This is the first study to identify a positive association between re-experiencing a traumatic event and
prostate cancer incidence. Our results are consistent with recent rodent model evidence demonstrating a direct
biological link between stress pathways and prostate tumorigenesis and offer new hypotheses in the causality of
prostate cancer.
Keywords: World trade center, Posttraumatic stress disorder, Prostate Cancer, Cancer epidemiology
Background
It has previously been reported that men who responded
to the 9/11/2001 events and worked on-site at the
World Trade Center (WTC) (hereafter: “responders”)
are experiencing a higher than expected incidence of
prostate cancer [1–4] and of more aggressive disease as
later stage diagnoses when compared to the NY state
cancer registry [3]. To date, however, efforts to identify
possible carcinogens and physical exposures have found
no link between the WTC physical exposures and the
observed increase in incidence of prostate cancer [4].
During these events, however, responders were exposed
to a host of emotional stressors both during the event
and in the months that followed and many responders,
in the years since, have reported having persistent and
chronic post-traumatic stress disorder (PTSD) [5].
While a few groups have provided evidence supporting
a link between stress and prostate cancer, recent work
from Zahalka et al. [6] provides important experimental
evidence for a direct link between the nervous system
and cancer in the prostate gland. Using genetic models
of prostate cancer and knock out studies, Zahlaka et al.
[6] demonstrated that autonomic nerves within the pros-
tate microenvironment were required for the activation
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of a metabolic switch necessary for exponential tumor
growth. This and previous mouse model studies of pros-
tate cancer implicate a direct role for intra-prostatic
sympathetic nerves and adrenergic signaling in angio-
genesis and tumor growth. Moreover, the β2-adrenergic
receptor (ADRB2) is implicated in differentiation of
prostate tumor cells to neuroendocrine-like cells, an
established histologic feature of aggressive prostate can-
cer. As reviewed by Braadland et al. [7], an emerging po-
tential consequence of sympathetic signaling to prostate
cancer, is evidence for prostatic nerve derived adrenergic
stimuli on adrenergic receptors in the tumor microenvir-
onment and direct effects on tumorigenesis. ADRB2 is
the most abundant receptor for adrenergic signals in
prostate luminal cells. Collectively, these data provide
biological plausibility that chronic hyperactivation of the
sympathetic nervous system while being chronically ex-
posed to a severe stressor, and its deregulation, may
have direct effects at the prostate tissue level.
Traumatic exposures, as occurred with the World
Trade Center attack, can cause a similar process
where individuals re-experience stress-inducing mem-
ories of their most severe stressors for a long time
after a traumatic event [8]. Importantly, when an in-
dividual is exposed to traumatic events, the brain ac-
tivates a host of neural systems including the
noradrenergic nucleus located in the locus coeruleus
in the midbrain [9]. Critically, the locus coeruleus
helps to regulate both emotional responses to external
stimuli [10], and activation of physical locomotion as
a response to stress [10]. The adrenergic response
also plays a key role in the activation of the amygdal-
oid complex, resulting in increased recognition and
improved storage of emotionally-intense experiences
[11]. For example, activation of α1-adrenergic recep-
tors engages the hippocampus to increase capacity for
long-term storage of traumatic memories for later re-
trieval and processing, while activation of the ADRB2
facilitates later retrieval of stressful memories [12].
During re-experienced memories, an individual can
react as though he or she is experiencing the stress.
This includes activation of the hypothalamic-pituitary-
adrenal axis [13] and resultant release of norepineph-
rine, which is critical to the fight or flight response
and activation of ADRB2. In addition to effects on
the amygdala and hippocampus to amplify and
process stressful memories [12], glucocorticoids are
activated to signal that the stress response is no lon-
ger necessary [14] thereby activating glucocorticoid
receptors [15]. Importantly, prostate cancer pathogen-
esis has been mechanistically linked to β-adrenergic
and glucocorticoid receptors, with evidence that dys-
functions in these pathways may be associated with
more aggressive forms of the disease [16].
Based on this evidence, we hypothesized that increased
re-experiencing stress severity may explain the increased
prostate cancer incidence observed in WTC responders.
Methods
Study population
This study utilized population-level data to examine risk
of prostate cancer in a clinical center that monitors
World Trade Center (WTC) responders residing in Long
Island, NY [17]. In this population of WTC responders,
more than 90% were working at the time of 9/11/2001,
and the majority were employed by the New York Police
Department. All monitored male WTC responders who
consented to participate in research studies were eligible
for this study (N = 6918). To reduce the risk of reverse
causation, 37 cases diagnosed since 9/11/2001 but prior
to the first monitoring visit were excluded from analyses.
Responders with missing data on confounders were ex-
cluded from analyses (n = 62); those who were excluded
had symptoms of PTSD similar to (p = 0.987) those who
were included in the study. The final analytic sample
therefore included 6857 eligible male responders con-
tributing a total of 47,261.2 person-years of information.
External reference population
The included WTC responders resided on Long Island,
NY. For comparison purposes to the local population
risk and cancer stage, we have utilized age-adjusted
prostate cancer incidence rates derived from the NY
state cancer registry for the most recent years available
(2010–2014) [18]. To account for geographic variability
in incidence of prostate cancer, sensitivity analyses also
calculated an inverse case-weighted average for Nassau
and Suffolk counties.
Assessment of prostate cancer incidence and severity
Prostate cancer (ICD-10: C61.9) was diagnosed during
regular clinical visits and confirmed by clinicians at the
Centers for Disease Control and Prevention. Date of
diagnosis and Gleason score were recorded. Histology
and cancer staging were recorded using a standard cod-
ing scheme [19]. For these analyses, cancer stage was
categorized into early (Stage I/II) and late-stage (Stage
III/IV). In some cases, a prostate cancer diagnosis
followed another cancer diagnosis; in these cases, the
date of the prostate-specific cancer diagnosis was re-
corded alongside the type of other cancer.
Assessment of PTSD symptoms
PTSD symptoms and symptom severity was measured at
study enrollment using the exposure-specific version of
the PTSD checklist that indexed symptoms specifically
to the WTC events (PCL) [20]. Individuals rated the ex-
tent to which they were bothered by seventeen PTSD
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symptoms in the past month. Ratings were made on a
scale ranging from 1 (not at all) to 5 (extremely). Since
animal studies implicated re-traumatization accompan-
ied by a heightened physiologic stress response, we here
focused on the five core re-experiencing symptoms (the
first five symptoms in the PCL) including: being both-
ered by disturbing memories, dreams, reliving the stress-
ful experience, upsetting reminders of the event, and
having a physical reaction to the reminders. The five re-
experiencing symptoms were averaged to provide a
symptom severity score using a validated methodology
[21] and then, to facilitate comparison of effect sizes
with other risk factors, the index was rescaled to range
from zero (0; no symptoms) to one (1; severe symp-
toms). Because there is no consistent guidance on inclu-
sion of continuous variables in regression analyses, for
effect size comparisons we also report hazards ratios
(HR) for PTSD reflecting a one-standard deviation
(HRSD) and interquartile range (HRIQR) increase in
PTSD symptoms.
Assessment of covariates
Age in years on 9/11/2001 was used. Body mass was cal-
culated using observed height in centimeters and weight
in kilograms. Race/ethnicity was categorized as non-
Hispanic White, non-Hispanic Black, non-Hispanic
other, and Hispanic. WTC exposure severity was assessed
using a structured history and answers formed the basis
for an index created using a validated measure relying
upon weights determined using a Delphi technique to
combine pulmonary exposure measures experienced at
the WTC both on 9/11/2001 and in the months after as
described [22].
Screening information
Since the risk of prostate cancer diagnosis is influenced
by the utilization of prostate-specific antigen (PSA)-
based prostate cancer screening, there is a potential for
bias if PTSD symptom severity influences the risk of
PSA-testing rates. Cancer screening for responders in
monitoring clinics follows the recommendations made
by the American Cancer Society [23]. Since American
Cancer Society guidelines advise against routine screen-
ing for prostate cancer, it is not provided to responders
at monitoring clinics. As such, the incidence of PSA test-
ing is unobserved. To capture the potential for increased
screening among those with PTSD symptoms, this study
examined whether PTSD symptom severity was associ-
ated with increased risk of referral for any other cancer
screening. For men, cancer screening is routinely pro-
vided for colorectal and lung cancers. To assess the po-
tential for screening bias we therefore examined whether
PTSD symptom severity was associated with increased
risk of receiving any cancer screening referral and,
secondarily, whether PTSD symptoms were associated
with increased adherence to cancer referrals. Cause-
specific cancer referrals and referral completion were
available between 01/01/2016–12/31/2017.
Statistical analysis
Means and standard deviations, as well as percentages
were used for descriptive purposes. Crude and age-
specific incidence rates were calculated. In descriptive
analyses, an exponential trend curve was overlaid on
age-specific rates using least squares regression. Age-
adjusted incidence rates were calculated using the direct
standardization approach weighted to the 2000 U.S.
standard population. Age-adjusted incidence rates were
used to calculate standardized incidence ratios (SIR), de-
fined as the ratio of observed incidence rates and ex-
pected incidence based on location-specific cancer
registry data. To examine differences in prostate cancer
staging, relative risks (RR) were calculated comparing to
NY state registry data. In all cases, 95% confidence inter-
vals were reported.
Log-binomial regression was used to model risk for re-
ceiving a referral for cancer screening when adjusting
for multiple confounders because cancer screening is a
common outcome [24]. Age and sex-adjusted risk ratios
(RR), 95% confidence intervals were estimated, and p-
values were provided.
The risk of receiving up to three cancer-screening op-
tions, conditional on being referred for cancer screening
was modeled using negative binomial regression. Nega-
tive binomial regression was used in lieu of Poisson re-
gression because rates were over-dispersed (α = 0.53), a
condition whereby the variance is larger than the mean
[25].
The risk of incident cancer was modeled using Cox
proportional hazards regression [26]. Cox models are a
semi-parametric form of survival modeling that reliably
models survival without incident prostate cancer under
the conditions that competing illnesses do not result in
decreased risk of incidence and in the event that the
proportional hazards assumption is met. Responders
were deemed to have entered the study on 9/11/2001.
Time until prostate cancer diagnosis was the outcome.
Responders were censored at their diagnosis or at their
last visit date. Hazards ratios and 95% confidence inter-
vals, as well as the cumulative hazards curve, were re-
ported. Schoenfeld residuals were used to test the
proportional hazards assumption.
Results
The monitoring program population was in early midlife
(average age = 37.9 ± 1.66 years [range = 16–75]) in 2001
and the majority were non-Hispanic White (Table 1).
Those who had diagnoses of prostate cancer were older,
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had more severe PTSD symptoms, and differed in Race/
Ethnicity than were those without prostate cancer.
A total of 68 eligible responders were diagnosed with
prostate cancer after their first monitoring visit (Crude
Incidence Rate (IR) = 152.34/100,000 95% C.I. =
[120.92–191.93]). The age-adjusted incidence rate was
(aIR = 267.36, [249.94–284.78]). Compared to SEER data,
WTC responders were at increased risk of developing
prostate cancer (SIR = 1.95, [1.55–2.44]). Sensitivity ana-
lyses relying only on Nassau and Suffolk counties, where
monitored responders reside, revealed similar overall re-
sults (SIR = 1.66, [1.31–2.07]).
In addition to prostate cancer, seven responders had at
least one additional comorbid cancer totaling 11 cancers,
including cancers of the lung/bronchus (n = 2), urinary
bladder (n = 2), colorectal (n = 2), kidney and renal pelvis
(n = 2), non-Hodgkin’s lymphoma (n = 1), stomach (n =
1), and thyroid (n = 1). Of these, most responders had
only one additional cancer, while one responder had two
and one had three.
Of those with diagnoses of prostate cancers, 67
(98.5%) had adenocarcinoma while one had an acinar
adenocarcinoma. Prostate cancers were staged as I
(n = 6), II (n = 25), III (n = 35), and IV (n = 1), with one
unknown, revealing that 31/68 (45.6%) were identified in
the early stage. Compared to the NY state average (Stage
I/II = 79.4% in 2014), WTC responders’ prostate cancers
were more likely to be identified at Stage III/IV (RR =
2.49, [1.98–3.13]).
Incidence rates of prostate cancer increased sharply
with age (Fig. 1). Incidence rates also differed by re-
experiencing symptom severity. Those with low re-
experiencing symptom severity scores ranging from
(0.00–0.10; n = 3100; 24 cancers) had age-adjusted inci-
dence rates of 250.83 [233.41–268.25], which increased
to 291.55 [2.74.13–308.97] in medium (score = 0.20–
0.49; n = 1947; 26 cancers), and 818.49 [801.07–835.91]
Table 1 Characteristics of the Stony Brook University World Trade Center Health and Wellness Program population
No Prostate cancer Prostate Cancer Diagnosis
Patient Characteristic Mean SD Mean SD P-value
Age at 9/11/2001 37.8 8.2 49.8 8.6 < 0.001
Re-experiencing symptoms 0.3 0.4 0.5 0.5 0.003
WTC Exposure Severity 14.5 4.5 14.5 4.4 0.919
Weeks worked at the WTC 5.3 4.5 5.4 4.6 0.814





Asian/Pacific Islander 0.8% –
American Indian/Alaskan Native 0.2% –
Multi-Race 0.4% 1.3%
Other/Unknown Race 16.0% 2.5%
Hispanic 7.1% 10.1%
Note: WTC: World Trade Center; SD: Standard Deviation; P-values were derived from Student’s t-test for continuous variables, and from Chi-Squared tests for
categorical variables
Fig. 1 Age-specific incidence rates. Blue bars provide age-specific
incidence rates. Black dotted line shows smoothed risk curve
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in high re-experiencing symptom severity (0.50–1.00;
n = 1810; 29 cancers) categories respectively.
Results from cancer screening analyses revealed that
half (51.5%) of all screening referrals in 2016/17 were
adhered with. Multivariable analyses revealed that re-
experiencing symptom severity was not associated with
the risk of receiving a cancer screening referral (aRR =
0.97 [0.73–1.29], P = 0.833), and that re-experiencing
symptom severity was not associated with increased risk
of adherence risk when patients were received a screen-
ing referral (aRR = 1.06 [0.80–1.41], P = 0.672).
Bivariable and multivariable incidence analyses revealed
that re-experiencing symptom severity was associated with
increased incidence of prostate cancer (HR = 3.87 [1.60–
9.36], P = 0.021) and the accompanying cumulative hazards
curve was provided (Fig. 2). This level of risk is
equivalent to an HRIQR = 1.40 [1.12–1.75] or a stan-
dardized effect size of HRSD = 1.32 [1.10–1.57]. Bivari-
ate results were corroborated in multivariable analyses
revealed similar results (Table 2). This level of risk is
equivalent to an aHRIQR = 1.40 [1.12–1.75] or a stan-
dardized effect size of aHRSD = 1.32 [1.10–1.57]. These
analyses also identified age with increased risk of prostate
cancer, and reporting “Other” race as being associated
with reduced risk of prostate cancer. Of potential interest,
risk of incident prostate cancer appeared more strongly
associated with PSD symptoms in men from other Races
(HR = 10.56 [1.54–72.33]), though the interaction effect
was not significant in these data (HR = 4.15, P = 0.256).
Schoenfeld residuals tests revealed that the study did not
violate proportional-hazards assumptions.
Discussion
In this study, data from an academic monitoring pro-
gram for WTC responders revealed a positive associ-
ation between re-experiencing symptom severity
following a traumatic event and risk of prostate cancer.
Replicating earlier efforts in a prior study showing that
included multiple monitoring clinics, we found that the
study sample is at heightened risk (SIR = 1.95 [1.55–
2.44]) for prostate cancer compared to state cancer
registries. Further, we provide the first evidence of a
small positive association between increased levels of re-
experiencing stress and incidence of prostate cancer
(HR = 1.96 [1.26–3.05], P = 0.003). To our knowledge,
this is the first prospective study to link any psychiatric
condition with incidence of cause-specific cancer.
Heightened incidence of prostate cancer has been pre-
viously reported in veterans [27] and early in WTC re-
sponders [1, 2]. For the latter, similar results have been
reported across the multiple cohorts of WTC exposed
populations and differences in screening do not appear
to account for the consistently elevated risk in these
groups [3, 4]. Despite extensive efforts, no plausible en-
vironmental exposure has been identified to account for
the higher rates in veterans or WTC responders. For ex-
ample, efforts to link Agent Orange to the increased risk
of prostate cancer are equivocal [27], as have been ef-
forts to link WTC exposure severity with elevated inci-
dence [28]. Other very large studies of prostate cancer
risk factors have also failed to identify any consistent risk
factors for prostate cancer and the etiology of prostate
cancer has remained elusive.
Fig. 2 Cumulative hazards curve examining prostate cancer incidence by PTSD symptom severity. Note: Re-experiencing symptom severity is
shown as no symptom severity (solid line; re-experiencing symptom scores = 0.00–0.10) compared to moderate scores (dashed line; scores
ranging from 0.11–0.49) and responders with severe re-experiencing symptom severity (dashed line; scores ranging from 0.50–1.00)
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More recently, animal model studies support direct ef-
fects of the nervous system in prostate cancer biology
and raise the possibility of stress effects on nervous sys-
tem derived signals in prostate cancer. Studies in
humans that support this causal hypothesis are limited.
Findings from epidemiological studies on the role of
stress in prostate cancer, are contradictory and limited
by lack of sufficiently large studies with quality measures
on stress exposures and too few outcomes to stratify on
cancer type [29–32]. Only a single prospective study re-
ported a positive association between perceived level of
stress and risk of prostate cancer over a five-year period
[33] while other studies that have linked screening-
induced anxiety to higher PSA levels are themselves
prone to symptom bias [34, 35]. In cancer patients, psy-
chological distress is associated with worse outcomes
[29, 31, 36, 37], which may suggest an underlying bio-
logical effect of stress in tumor behavior though psycho-
social impacts on access and use of cancer treatment
remain potential confounders. Interestingly and consist-
ent with the animal data is limited epidemiologic evi-
dence that β-blockers used to inhibit the action of
ADRB2 are associated with lower prostate cancer mor-
tality [38]. Perhaps the strongest epidemiologic evidence
for ‘stress’ and prostate cancer are findings from the
Physicians’ Health/Health Professionals Follow-Up Study
[39] that compared gene expression profiles in 254 pros-
tate cancers and 120 normal tissues from cohort partici-
pants. In their study, Lu et.al. demonstrated that stress-
related signaling pathways, including adrenergic and
glucocorticoid genes and their associated pathways, were
positively associated with a more lethal form of prostate
cancer and worse survival.
This work builds on evidence that re-experiencing
symptoms provoke the body’s fight or flight response
mechanisms linking PTSD symptoms to deregulated
glucocorticoid and β-adrenergic receptor activation in
the periphery. Important to our study, most responders
with re-experiencing symptoms (used here) do not attain
the level of severity and of functional limitations neces-
sary for a clinical diagnosis of PTSD. For example, only
10% of responders are currently diagnosed with PTSD
[5], whereas 32.9% are categorized as having medium
levels of re-experiencing symptoms and 21.7% have high
PTSD symptomatology in this study. Future efforts to
replicate the observed increased prostate cancer risks as-
sociated with PTSD in our study should consider the
role of PTSD symptom types in populations and prostate
cancer risk.
Strengths and limitations
This is one of the only studies to examine the poten-
tial for posttraumatic re-experiencing symptom sever-
ity to increase the risk of prostate cancer. Unlike
many studies, this study is notable because re-
experiencing symptoms were measured at enrollment
and therefore, by design, prior to the diagnosis of in-
cident prostate cancer. Diagnoses were identified fol-
lowing strict guidelines, and adherence to these
guidelines was independently verified by staff at the
Centers for Disease Control and Prevention.
A primary limitation is the relative youth of the study
cohort as a whole (aged 54 on average in January 2018)
since 57% of all prostate cancers are diagnosed in men
aged 65 and older [40]. Additionally, the cohort is pri-
marily non-Hispanic White with relatively respectable
jobs who served in a response effort to a unique but se-
verely stressful event and live in Long Island, NY. These
factors limit the generalizability of this result in mean-
ingful ways. Notably, there is good evidence to suggest
that African Americans are at increased risk of prostate
cancer, which may make that population uniquely vul-
nerable to additional risk due to stress-based exposures,
and hypothesis that was not interrogated here due to the
small number of cancers overall. In our data, African
Americans were not at significantly increased risk al-
though there was a non-significant trend towards a
stronger association between re-experiencing symptoms
and incidence of prostate cancer in African Americans.
Improving generalizability and extending results to mi-
norities will require larger, more diverse samples and/or
longer follow-up periods. There is limited information
about the role of screening in this population. While be-
ing a clinical cohort, it is worthwhile noting that the
monitoring program has never provided screening as a
matter of course to WTC responders. While it is plaus-
ible that screening may be more common off-site among
responders as a group, screening and severity indicators
interrogated herein suggest that this is unlikely. Specific-
ally, when compared to state registry data suggesting
that 20.6% of prostate cancers are diagnosed at Stages
Table 2 Multivariable adjusted hazards ratios and 95%
Confidence Intervals derived from Cox proportional hazards
regression examining predictors of prostate cancer incidence
since 9/11/2001
Characteristic aHR 95% C.I. P
Re-experiencing symptom severity 3.50 [1.37–8.96] 0.009
Age on 9/11/2001 1.14 [1.12–1.17] 0.000
Exposure severity 0.99 [0.86–1.14] 0.871
Body Mass 0.98 [0.94–1.02] 0.344
Race/Ethnicity
White 1.00
Black 1.35 [0.49–3.72] 0.563
Other 0.20 [0.06–0.63] 0.006
Hispanic 1.59 [0.76–3.32] 0.218
Note: aHR: multivariable-adjusted hazard ratio
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III/IV, we found that 40/78 (51.3%) of prostate cancers
were identified in Stages III/IV (RR = 2.49 [1.98–3.13]).
Additionally, we found no suggestion that PTSD symp-
tom severity might increase risk of cancer screening re-
ferral and completion, and also found that completion
was relatively low. Finally, there are a number of other
conditions including lifetime risk of mood disorders
[41], major depressive disorder [42], and manic disorders
[43] that have been linked with increased risk of PTSD
after a trauma and may, therefore, play a heretofore un-
known role in determining the risk of prostate cancer.
Together, these results suggest that while there remains
the potential for screening bias, the extent of this bias
may be limited.
Conclusions
This study identified a novel association between in-
creased PTSD re-experiencing symptom severity and in-
creased incidence of prostate cancer in a cohort of WTC
responders who were prospectively monitored for cancer
as part of an academic monitoring program. The bio-
logical plausibility of our observation is supported by
findings from experimental models of prostate tumori-
genesis and if replicated, may represent an important
step towards understanding pathogenesis of prostate
cancer in traumatized populations.
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